This trial is active, not recruiting.

Condition osteoarthritis of the shoulder
Treatments zimmer tm glenoid, cemented glenoid
Sponsor Joint Preservation Centre of BC
Start date April 2012
End date December 2018
Trial size 104 participants
Trial identifier NCT01539122, TMGlenoid H12-00323


The objective of this randomized controlled study is to obtain outcomes data on the Zimmer TM glenoid component by analysis of standard scoring systems and radiographs in comparison to the cemented glenoid component. In addition, the investigators plan to provide cost analysis based on the economic data collected to justify the cost difference between both implants.

Patients with acceptable glenoid bone stock will be randomized into two groups to be treated with either a TM Glenoid or cemented glenoid component with minimum 2 years follow-up; maximum 10 years follow-up.

Hypothesis: The early and long-term clinical outcomes and radiographic analysis of the TM glenoid components are superior to the cemented glenoid components in total shoulder arthroplasty patients.

United States No locations recruiting
Other countries No locations recruiting

Study Design

Allocation randomized
Intervention model parallel assignment
Masking open label
Primary purpose treatment
(Active Comparator)
Zimmer TM glenoid shoulder replacement component will be used for the glenoid component of the total shoulder replacement.
zimmer tm glenoid Zimmer Trabecular Metal Glenoid
The Zimmer TM glenoid will be used for the glenoid shoulder replacement component.
(Active Comparator)
Cemented glenoid shoulder replacement component
cemented glenoid Cemented all-polyethylene glenoid component (Zimmer)
A cemented glenoid will be used for the glenoid component of the total shoulder replacement.

Primary Outcomes

Change in Western Ontario Arthritis of the Shoulder Index (WOOS)
time frame: 6 weeks, 3 mo, 6 mo, 1 yr, 2 yr, 3 yr, 4 yr, 5 yr post-op

Secondary Outcomes

Change in ASES score
time frame: 6 weeks, 3 mo, 6 mo, 1 yr, 2 yr, 3 yr, 4 yr, 5 yr post-op
Change in Short Form 12 (SF-12)
time frame: 6 weeks, 3 mo, 6 mo, 1 yr, 2 yr, 3 yr, 4 yr, 5 yr post-op
Change in Health Resource Utilization Instrument
time frame: 6 weeks, 3 mo, 6 mo, 1 yr, 2 yr, 3 yr, 4 yr, 5 yr post-op
Change in Radiographic evaluation
time frame: post-op day 0 or 1, 6 weeks, 3 months, 6 months, 1 yr, 2 yr, 3 yr, 4 yr, 5 yr post-op

Eligibility Criteria

Male or female participants from 18 years up to 80 years old.

Inclusion Criteria: - Age - 18 years minimum and 80 years of age maximum. - Gender - male and female. - Primary Diagnosis: Primary Glenohumeral Osteoarthritis - Informed Consent - patient has signed a 'Patient Informed Consent form' - Surgery date: Beginning on January 1, 2012 - KEY Inclusion Criteria: The critical inclusion criteria for patient selection for TM or Cemented glenoid prosthesis are based on adequacy of glenoid bone stock/quality at time of implantation. Pre-operative CT scans and intra-operative decision of the surgeon at time of surgery will determine the issue of bone stock/quality. Exclusion Criteria: - Age > 80 years - Significant Bone Loss (classified as concentric vs eccentric; contained vs uncontained) on pre-operative CT scan requiring cemented prosthesis. - Evidence of major joint trauma, infection, avascular necrosis, cuff tear arthropathy, inflammatory arthropathy, chronic dislocation, massive rotator cuff tear or previous shoulder surgery (other than arthroscopic debridement) - Preoperative computed tomography scans of the shoulder that showed insufficient glenoid bone stock to allow for implantation of a glenoid prosthesis - Active joint or systematic infection, significant muscle paralysis, or Charcot arthropathy - Life expectancy of less than 2 years or unacceptably high operative risk - Inability to speak or read English - Psychiatric illness or cognitive deficit that precluded informed consent - Unwillingness to be followed up for 5 years

Additional Information

Official title A Multi-Centre, Randomized Controlled Study on the Zimmer TM Glenoid Component Compared to Cemented Glenoid Component
Principal investigator Patrick Chin, MD,FRCSC,MBA
Description Total shoulder arthroplasty is successful in relieving pain and restoring function to the joint, but chronic loosening of the glenoid implant remains a common complication. The Zimmer Trabecular Metal (TM) Glenoid is a monoblock implant for reconstructive total shoulder arthroplasty. To date, no published clinical data is available to confirm evidence on the effectiveness of this specific product. The purpose of this prospective study is to obtain both short and long-term clinical outcomes data on the Zimmer TM Glenoid by analysis of standard scoring systems and radiographic analysis. The TM Glenoid Component is intended to function within Zimmer, Inc.'s Bigliani/Flatow (B/F) Complete Shoulder Solution. The device is a monoblock glenoid component comprised of a Trabecular Metal base, and is designed to interface and articulate with Zimmer, Inc.'s B/F humeral components. The Trabecular Metal Glenoid is designed with an articular surface that is manufactured from ultra-high molecular weight polyethylene (UHMWPE). The base of the implant has a cruciate TM keel that provides stability and initial fixation using a press-fit between the implant and the bone. Long-term fixation is provided by biological ingrowth into the TM material. Surgical fixation of the trabecular metal device will be obtained via press-fit. Surgical fixation of the comparison all-polyethylene glenoid component will be with Palacos/CoPal bone cement This is a multi-centre, randomized controlled study to evaluate the clinical and radiological performance of the TM Glenoid in a series of patients with adequate glenoid bone stock receiving a total shoulder replacement. The comparison group will be a consecutive series of randomized patients with implanted cemented all-polyethylene glenoid component. This study will be descriptive in nature and seeks to demonstrate the superiority (or non-inferiority) of the TM Glenoid over cemented all-polyethylene glenoid components.
Trial information was received from ClinicalTrials.gov and was last updated in November 2015.
Information provided to ClinicalTrials.gov by Joint Preservation Centre of BC.